nodes	percent_of_prediction	percent_of_DWPC	metapath
Sildenafil—CYP3A4—bone cancer	0.324	1	CbGaD
Sildenafil—ABCC5—Cisplatin—bone cancer	0.171	0.354	CbGbCtD
Sildenafil—ABCC10—Doxorubicin—bone cancer	0.114	0.237	CbGbCtD
Sildenafil—ABCC10—Methotrexate—bone cancer	0.111	0.23	CbGbCtD
Sildenafil—ABCC4—Methotrexate—bone cancer	0.0532	0.11	CbGbCtD
Sildenafil—CYP2C9—Cisplatin—bone cancer	0.0164	0.034	CbGbCtD
Sildenafil—CYP2D6—Doxorubicin—bone cancer	0.01	0.0208	CbGbCtD
Sildenafil—CYP3A4—Doxorubicin—bone cancer	0.00638	0.0132	CbGbCtD
Sildenafil—Udenafil—CYP3A4—bone cancer	0.00261	0.597	CrCbGaD
Sildenafil—Vardenafil—CYP3A4—bone cancer	0.00176	0.403	CrCbGaD
Sildenafil—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000282	0.00563	CbGpPWpGaD
Sildenafil—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000273	0.00545	CbGpPWpGaD
Sildenafil—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000271	0.0054	CbGpPWpGaD
Sildenafil—ABCC10—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000266	0.00532	CbGpPWpGaD
Sildenafil—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000247	0.00494	CbGpPWpGaD
Sildenafil—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000244	0.00487	CbGpPWpGaD
Sildenafil—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.000229	0.00458	CbGpPWpGaD
Sildenafil—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000228	0.00456	CbGpPWpGaD
Sildenafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000224	0.00447	CbGpPWpGaD
Sildenafil—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000221	0.00442	CbGpPWpGaD
Sildenafil—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	0.000209	0.00417	CbGpPWpGaD
Sildenafil—ABCC5—Fluoropyrimidine Activity—TP53—bone cancer	0.000209	0.00417	CbGpPWpGaD
Sildenafil—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000208	0.00416	CbGpPWpGaD
Sildenafil—ABCC5—NRF2 pathway—GSTP1—bone cancer	0.000206	0.00412	CbGpPWpGaD
Sildenafil—ABCC5—NRF2 pathway—TGFBR2—bone cancer	0.000206	0.00412	CbGpPWpGaD
Sildenafil—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.0002	0.004	CbGpPWpGaD
Sildenafil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000198	0.00396	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—SPARC—bone cancer	0.000194	0.00387	CbGpPWpGaD
Sildenafil—ABCC5—Carbohydrate metabolism—ENO2—bone cancer	0.000194	0.00387	CbGpPWpGaD
Sildenafil—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000179	0.00358	CbGpPWpGaD
Sildenafil—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000179	0.00357	CbGpPWpGaD
Sildenafil—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000178	0.00356	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—GNA11—bone cancer	0.000177	0.00354	CbGpPWpGaD
Sildenafil—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000177	0.00353	CbGpPWpGaD
Sildenafil—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000176	0.00352	CbGpPWpGaD
Sildenafil—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000169	0.00337	CbGpPWpGaD
Sildenafil—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000167	0.00333	CbGpPWpGaD
Sildenafil—ADORA2A—Circadian rythm related genes—GNA11—bone cancer	0.000163	0.00325	CbGpPWpGaD
Sildenafil—ABCC5—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000162	0.00324	CbGpPWpGaD
Sildenafil—ADORA2A—Circadian rythm related genes—EZH2—bone cancer	0.000162	0.00323	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—IL3—bone cancer	0.000161	0.00321	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR ligand binding—GRM4—bone cancer	0.000156	0.00311	CbGpPWpGaD
Sildenafil—Photosensitivity reaction—Doxorubicin—bone cancer	0.000154	0.0011	CcSEcCtD
Sildenafil—Weight increased—Doxorubicin—bone cancer	0.000154	0.00109	CcSEcCtD
Sildenafil—Epistaxis—Epirubicin—bone cancer	0.000154	0.00109	CcSEcCtD
Sildenafil—Urethral disorder—Methotrexate—bone cancer	0.000153	0.00109	CcSEcCtD
Sildenafil—Sinusitis—Epirubicin—bone cancer	0.000153	0.00109	CcSEcCtD
Sildenafil—Hyperglycaemia—Doxorubicin—bone cancer	0.000152	0.00108	CcSEcCtD
Sildenafil—Pneumonia—Doxorubicin—bone cancer	0.000152	0.00108	CcSEcCtD
Sildenafil—Infestation—Doxorubicin—bone cancer	0.000151	0.00107	CcSEcCtD
Sildenafil—Infestation NOS—Doxorubicin—bone cancer	0.000151	0.00107	CcSEcCtD
Sildenafil—Visual impairment—Methotrexate—bone cancer	0.000151	0.00107	CcSEcCtD
Sildenafil—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000149	0.00106	CcSEcCtD
Sildenafil—Hypersensitivity—Cisplatin—bone cancer	0.000149	0.00106	CcSEcCtD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—ATF1—bone cancer	0.000148	0.00296	CbGpPWpGaD
Sildenafil—Renal failure—Doxorubicin—bone cancer	0.000148	0.00105	CcSEcCtD
Sildenafil—Erythema multiforme—Methotrexate—bone cancer	0.000148	0.00105	CcSEcCtD
Sildenafil—Neuropathy peripheral—Doxorubicin—bone cancer	0.000148	0.00105	CcSEcCtD
Sildenafil—Haemoglobin—Epirubicin—bone cancer	0.000147	0.00104	CcSEcCtD
Sildenafil—Stomatitis—Doxorubicin—bone cancer	0.000147	0.00104	CcSEcCtD
Sildenafil—Rhinitis—Epirubicin—bone cancer	0.000147	0.00104	CcSEcCtD
Sildenafil—Urinary tract infection—Doxorubicin—bone cancer	0.000146	0.00104	CcSEcCtD
Sildenafil—Conjunctivitis—Doxorubicin—bone cancer	0.000146	0.00104	CcSEcCtD
Sildenafil—Haemorrhage—Epirubicin—bone cancer	0.000146	0.00104	CcSEcCtD
Sildenafil—Eye disorder—Methotrexate—bone cancer	0.000146	0.00104	CcSEcCtD
Sildenafil—Tinnitus—Methotrexate—bone cancer	0.000146	0.00104	CcSEcCtD
Sildenafil—Hypoaesthesia—Epirubicin—bone cancer	0.000145	0.00103	CcSEcCtD
Sildenafil—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000145	0.0029	CbGpPWpGaD
Sildenafil—Asthenia—Cisplatin—bone cancer	0.000145	0.00103	CcSEcCtD
Sildenafil—Pharyngitis—Epirubicin—bone cancer	0.000145	0.00103	CcSEcCtD
Sildenafil—Cardiac disorder—Methotrexate—bone cancer	0.000145	0.00103	CcSEcCtD
Sildenafil—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000145	0.00289	CbGpPWpGaD
Sildenafil—ABCC4—Fluoropyrimidine Activity—TP53—bone cancer	0.000145	0.00289	CbGpPWpGaD
Sildenafil—ABCC4—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000145	0.00289	CbGpPWpGaD
Sildenafil—Sweating—Doxorubicin—bone cancer	0.000144	0.00103	CcSEcCtD
Sildenafil—Urinary tract disorder—Epirubicin—bone cancer	0.000144	0.00103	CcSEcCtD
Sildenafil—Oedema peripheral—Epirubicin—bone cancer	0.000144	0.00102	CcSEcCtD
Sildenafil—Haematuria—Doxorubicin—bone cancer	0.000144	0.00102	CcSEcCtD
Sildenafil—Connective tissue disorder—Epirubicin—bone cancer	0.000144	0.00102	CcSEcCtD
Sildenafil—Urethral disorder—Epirubicin—bone cancer	0.000143	0.00102	CcSEcCtD
Sildenafil—ABCC4—NRF2 pathway—GSTP1—bone cancer	0.000143	0.00285	CbGpPWpGaD
Sildenafil—ABCC4—NRF2 pathway—TGFBR2—bone cancer	0.000143	0.00285	CbGpPWpGaD
Sildenafil—Epistaxis—Doxorubicin—bone cancer	0.000142	0.00101	CcSEcCtD
Sildenafil—Angiopathy—Methotrexate—bone cancer	0.000142	0.00101	CcSEcCtD
Sildenafil—Sinusitis—Doxorubicin—bone cancer	0.000141	0.001	CcSEcCtD
Sildenafil—Immune system disorder—Methotrexate—bone cancer	0.000141	0.001	CcSEcCtD
Sildenafil—Visual impairment—Epirubicin—bone cancer	0.000141	0.001	CcSEcCtD
Sildenafil—Mediastinal disorder—Methotrexate—bone cancer	0.000141	0.001	CcSEcCtD
Sildenafil—Chills—Methotrexate—bone cancer	0.00014	0.000996	CcSEcCtD
Sildenafil—ABCC5—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00014	0.00279	CbGpPWpGaD
Sildenafil—Diarrhoea—Cisplatin—bone cancer	0.000138	0.000984	CcSEcCtD
Sildenafil—Erythema multiforme—Epirubicin—bone cancer	0.000138	0.000982	CcSEcCtD
Sildenafil—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000138	0.00276	CbGpPWpGaD
Sildenafil—Alopecia—Methotrexate—bone cancer	0.000138	0.000981	CcSEcCtD
Sildenafil—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000137	0.00273	CbGpPWpGaD
Sildenafil—Mental disorder—Methotrexate—bone cancer	0.000137	0.000973	CcSEcCtD
Sildenafil—Eye disorder—Epirubicin—bone cancer	0.000137	0.000971	CcSEcCtD
Sildenafil—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000136	0.00272	CbGpPWpGaD
Sildenafil—Tinnitus—Epirubicin—bone cancer	0.000136	0.000969	CcSEcCtD
Sildenafil—Erythema—Methotrexate—bone cancer	0.000136	0.000967	CcSEcCtD
Sildenafil—Malnutrition—Methotrexate—bone cancer	0.000136	0.000967	CcSEcCtD
Sildenafil—Haemoglobin—Doxorubicin—bone cancer	0.000136	0.000966	CcSEcCtD
Sildenafil—Cardiac disorder—Epirubicin—bone cancer	0.000136	0.000964	CcSEcCtD
Sildenafil—Flushing—Epirubicin—bone cancer	0.000136	0.000964	CcSEcCtD
Sildenafil—Rhinitis—Doxorubicin—bone cancer	0.000136	0.000964	CcSEcCtD
Sildenafil—Haemorrhage—Doxorubicin—bone cancer	0.000135	0.000961	CcSEcCtD
Sildenafil—ADORA2A—GPCR ligand binding—GRM1—bone cancer	0.000135	0.00269	CbGpPWpGaD
Sildenafil—Hypoaesthesia—Doxorubicin—bone cancer	0.000135	0.000957	CcSEcCtD
Sildenafil—Pharyngitis—Doxorubicin—bone cancer	0.000134	0.000954	CcSEcCtD
Sildenafil—Urinary tract disorder—Doxorubicin—bone cancer	0.000134	0.000949	CcSEcCtD
Sildenafil—Oedema peripheral—Doxorubicin—bone cancer	0.000133	0.000947	CcSEcCtD
Sildenafil—Connective tissue disorder—Doxorubicin—bone cancer	0.000133	0.000945	CcSEcCtD
Sildenafil—Angiopathy—Epirubicin—bone cancer	0.000133	0.000943	CcSEcCtD
Sildenafil—Urethral disorder—Doxorubicin—bone cancer	0.000133	0.000942	CcSEcCtD
Sildenafil—ABCC4—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000132	0.00264	CbGpPWpGaD
Sildenafil—Immune system disorder—Epirubicin—bone cancer	0.000132	0.000939	CcSEcCtD
Sildenafil—Mediastinal disorder—Epirubicin—bone cancer	0.000132	0.000936	CcSEcCtD
Sildenafil—Back pain—Methotrexate—bone cancer	0.000132	0.000935	CcSEcCtD
Sildenafil—Chills—Epirubicin—bone cancer	0.000131	0.000932	CcSEcCtD
Sildenafil—Arrhythmia—Epirubicin—bone cancer	0.000131	0.000928	CcSEcCtD
Sildenafil—Visual impairment—Doxorubicin—bone cancer	0.00013	0.000927	CcSEcCtD
Sildenafil—Alopecia—Epirubicin—bone cancer	0.000129	0.000918	CcSEcCtD
Sildenafil—Vomiting—Cisplatin—bone cancer	0.000129	0.000914	CcSEcCtD
Sildenafil—Vision blurred—Methotrexate—bone cancer	0.000128	0.000911	CcSEcCtD
Sildenafil—Mental disorder—Epirubicin—bone cancer	0.000128	0.00091	CcSEcCtD
Sildenafil—Erythema multiforme—Doxorubicin—bone cancer	0.000128	0.000909	CcSEcCtD
Sildenafil—Rash—Cisplatin—bone cancer	0.000127	0.000906	CcSEcCtD
Sildenafil—Dermatitis—Cisplatin—bone cancer	0.000127	0.000906	CcSEcCtD
Sildenafil—Malnutrition—Epirubicin—bone cancer	0.000127	0.000905	CcSEcCtD
Sildenafil—Erythema—Epirubicin—bone cancer	0.000127	0.000905	CcSEcCtD
Sildenafil—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000127	0.00254	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—NDUFA12—bone cancer	0.000127	0.00253	CbGpPWpGaD
Sildenafil—Eye disorder—Doxorubicin—bone cancer	0.000126	0.000899	CcSEcCtD
Sildenafil—Ill-defined disorder—Methotrexate—bone cancer	0.000126	0.000897	CcSEcCtD
Sildenafil—Tinnitus—Doxorubicin—bone cancer	0.000126	0.000896	CcSEcCtD
Sildenafil—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000126	0.00252	CbGpPWpGaD
Sildenafil—Anaemia—Methotrexate—bone cancer	0.000126	0.000893	CcSEcCtD
Sildenafil—Flushing—Doxorubicin—bone cancer	0.000126	0.000892	CcSEcCtD
Sildenafil—Cardiac disorder—Doxorubicin—bone cancer	0.000126	0.000892	CcSEcCtD
Sildenafil—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000125	0.0025	CbGpPWpGaD
Sildenafil—Flatulence—Epirubicin—bone cancer	0.000125	0.000891	CcSEcCtD
Sildenafil—Tension—Epirubicin—bone cancer	0.000125	0.000888	CcSEcCtD
Sildenafil—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000124	0.00248	CbGpPWpGaD
Sildenafil—Nervousness—Epirubicin—bone cancer	0.000124	0.000879	CcSEcCtD
Sildenafil—Back pain—Epirubicin—bone cancer	0.000123	0.000875	CcSEcCtD
Sildenafil—Angiopathy—Doxorubicin—bone cancer	0.000123	0.000872	CcSEcCtD
Sildenafil—Malaise—Methotrexate—bone cancer	0.000123	0.000872	CcSEcCtD
Sildenafil—Immune system disorder—Doxorubicin—bone cancer	0.000122	0.000868	CcSEcCtD
Sildenafil—Vertigo—Methotrexate—bone cancer	0.000122	0.000868	CcSEcCtD
Sildenafil—Mediastinal disorder—Doxorubicin—bone cancer	0.000122	0.000867	CcSEcCtD
Sildenafil—Leukopenia—Methotrexate—bone cancer	0.000122	0.000865	CcSEcCtD
Sildenafil—Chills—Doxorubicin—bone cancer	0.000121	0.000863	CcSEcCtD
Sildenafil—Arrhythmia—Doxorubicin—bone cancer	0.000121	0.000859	CcSEcCtD
Sildenafil—Nausea—Cisplatin—bone cancer	0.00012	0.000854	CcSEcCtD
Sildenafil—Vision blurred—Epirubicin—bone cancer	0.00012	0.000852	CcSEcCtD
Sildenafil—ABCC4—Platelet activation, signaling and aggregation—IL3—bone cancer	0.00012	0.00239	CbGpPWpGaD
Sildenafil—Alopecia—Doxorubicin—bone cancer	0.000119	0.00085	CcSEcCtD
Sildenafil—Cough—Methotrexate—bone cancer	0.000119	0.000843	CcSEcCtD
Sildenafil—Mental disorder—Doxorubicin—bone cancer	0.000118	0.000842	CcSEcCtD
Sildenafil—Ill-defined disorder—Epirubicin—bone cancer	0.000118	0.000839	CcSEcCtD
Sildenafil—Convulsion—Methotrexate—bone cancer	0.000118	0.000837	CcSEcCtD
Sildenafil—Erythema—Doxorubicin—bone cancer	0.000118	0.000837	CcSEcCtD
Sildenafil—Malnutrition—Doxorubicin—bone cancer	0.000118	0.000837	CcSEcCtD
Sildenafil—Anaemia—Epirubicin—bone cancer	0.000118	0.000836	CcSEcCtD
Sildenafil—Agitation—Epirubicin—bone cancer	0.000117	0.000831	CcSEcCtD
Sildenafil—Flatulence—Doxorubicin—bone cancer	0.000116	0.000825	CcSEcCtD
Sildenafil—Arthralgia—Methotrexate—bone cancer	0.000116	0.000823	CcSEcCtD
Sildenafil—Myalgia—Methotrexate—bone cancer	0.000116	0.000823	CcSEcCtD
Sildenafil—Chest pain—Methotrexate—bone cancer	0.000116	0.000823	CcSEcCtD
Sildenafil—Tension—Doxorubicin—bone cancer	0.000116	0.000821	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000115	0.000817	CcSEcCtD
Sildenafil—Malaise—Epirubicin—bone cancer	0.000115	0.000816	CcSEcCtD
Sildenafil—Discomfort—Methotrexate—bone cancer	0.000114	0.000813	CcSEcCtD
Sildenafil—Nervousness—Doxorubicin—bone cancer	0.000114	0.000813	CcSEcCtD
Sildenafil—Vertigo—Epirubicin—bone cancer	0.000114	0.000813	CcSEcCtD
Sildenafil—Syncope—Epirubicin—bone cancer	0.000114	0.000811	CcSEcCtD
Sildenafil—ADORA2A—Signaling by NGF—ATF1—bone cancer	0.000114	0.00228	CbGpPWpGaD
Sildenafil—Leukopenia—Epirubicin—bone cancer	0.000114	0.00081	CcSEcCtD
Sildenafil—Back pain—Doxorubicin—bone cancer	0.000114	0.00081	CcSEcCtD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000113	0.00225	CbGpPWpGaD
Sildenafil—Palpitations—Epirubicin—bone cancer	0.000112	0.000799	CcSEcCtD
Sildenafil—ABCC4—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000112	0.00224	CbGpPWpGaD
Sildenafil—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000112	0.00224	CbGpPWpGaD
Sildenafil—Loss of consciousness—Epirubicin—bone cancer	0.000112	0.000795	CcSEcCtD
Sildenafil—Cough—Epirubicin—bone cancer	0.000111	0.000789	CcSEcCtD
Sildenafil—Vision blurred—Doxorubicin—bone cancer	0.000111	0.000789	CcSEcCtD
Sildenafil—PDE6G—Signaling Pathways—RGS1—bone cancer	0.00011	0.00221	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—GRM4—bone cancer	0.00011	0.00221	CbGpPWpGaD
Sildenafil—Convulsion—Epirubicin—bone cancer	0.00011	0.000784	CcSEcCtD
Sildenafil—Infection—Methotrexate—bone cancer	0.00011	0.000784	CcSEcCtD
Sildenafil—Hypertension—Epirubicin—bone cancer	0.00011	0.000781	CcSEcCtD
Sildenafil—Ill-defined disorder—Doxorubicin—bone cancer	0.000109	0.000777	CcSEcCtD
Sildenafil—Nervous system disorder—Methotrexate—bone cancer	0.000109	0.000774	CcSEcCtD
Sildenafil—Anaemia—Doxorubicin—bone cancer	0.000109	0.000774	CcSEcCtD
Sildenafil—Chest pain—Epirubicin—bone cancer	0.000108	0.00077	CcSEcCtD
Sildenafil—Myalgia—Epirubicin—bone cancer	0.000108	0.00077	CcSEcCtD
Sildenafil—Arthralgia—Epirubicin—bone cancer	0.000108	0.00077	CcSEcCtD
Sildenafil—Agitation—Doxorubicin—bone cancer	0.000108	0.000769	CcSEcCtD
Sildenafil—Anxiety—Epirubicin—bone cancer	0.000108	0.000767	CcSEcCtD
Sildenafil—Skin disorder—Methotrexate—bone cancer	0.000108	0.000766	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000108	0.000765	CcSEcCtD
Sildenafil—Hyperhidrosis—Methotrexate—bone cancer	0.000107	0.000763	CcSEcCtD
Sildenafil—Discomfort—Epirubicin—bone cancer	0.000107	0.000761	CcSEcCtD
Sildenafil—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000106	0.00213	CbGpPWpGaD
Sildenafil—Malaise—Doxorubicin—bone cancer	0.000106	0.000755	CcSEcCtD
Sildenafil—Dry mouth—Epirubicin—bone cancer	0.000106	0.000753	CcSEcCtD
Sildenafil—Vertigo—Doxorubicin—bone cancer	0.000106	0.000752	CcSEcCtD
Sildenafil—Anorexia—Methotrexate—bone cancer	0.000106	0.000752	CcSEcCtD
Sildenafil—Syncope—Doxorubicin—bone cancer	0.000106	0.000751	CcSEcCtD
Sildenafil—PDE5A—Hemostasis—PLAU—bone cancer	0.000105	0.00211	CbGpPWpGaD
Sildenafil—Leukopenia—Doxorubicin—bone cancer	0.000105	0.000749	CcSEcCtD
Sildenafil—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000105	0.0021	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—NT5C3A—bone cancer	0.000105	0.0021	CbGpPWpGaD
Sildenafil—Palpitations—Doxorubicin—bone cancer	0.000104	0.00074	CcSEcCtD
Sildenafil—Oedema—Epirubicin—bone cancer	0.000104	0.000738	CcSEcCtD
Sildenafil—Hypotension—Methotrexate—bone cancer	0.000104	0.000737	CcSEcCtD
Sildenafil—Loss of consciousness—Doxorubicin—bone cancer	0.000103	0.000736	CcSEcCtD
Sildenafil—Infection—Epirubicin—bone cancer	0.000103	0.000733	CcSEcCtD
Sildenafil—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000103	0.00206	CbGpPWpGaD
Sildenafil—Cough—Doxorubicin—bone cancer	0.000103	0.00073	CcSEcCtD
Sildenafil—Shock—Epirubicin—bone cancer	0.000102	0.000726	CcSEcCtD
Sildenafil—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000102	0.00204	CbGpPWpGaD
Sildenafil—Convulsion—Doxorubicin—bone cancer	0.000102	0.000725	CcSEcCtD
Sildenafil—Nervous system disorder—Epirubicin—bone cancer	0.000102	0.000724	CcSEcCtD
Sildenafil—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000102	0.00203	CbGpPWpGaD
Sildenafil—PDE6G—Disease—ENO2—bone cancer	0.000102	0.00203	CbGpPWpGaD
Sildenafil—Hypertension—Doxorubicin—bone cancer	0.000102	0.000723	CcSEcCtD
Sildenafil—Tachycardia—Epirubicin—bone cancer	0.000101	0.000721	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000101	0.000719	CcSEcCtD
Sildenafil—Skin disorder—Epirubicin—bone cancer	0.000101	0.000717	CcSEcCtD
Sildenafil—Hyperhidrosis—Epirubicin—bone cancer	0.0001	0.000714	CcSEcCtD
Sildenafil—Insomnia—Methotrexate—bone cancer	0.0001	0.000713	CcSEcCtD
Sildenafil—Arthralgia—Doxorubicin—bone cancer	0.0001	0.000713	CcSEcCtD
Sildenafil—Chest pain—Doxorubicin—bone cancer	0.0001	0.000713	CcSEcCtD
Sildenafil—Myalgia—Doxorubicin—bone cancer	0.0001	0.000713	CcSEcCtD
Sildenafil—Anxiety—Doxorubicin—bone cancer	9.99e-05	0.00071	CcSEcCtD
Sildenafil—Paraesthesia—Methotrexate—bone cancer	9.96e-05	0.000708	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	9.95e-05	0.000708	CcSEcCtD
Sildenafil—Discomfort—Doxorubicin—bone cancer	9.9e-05	0.000704	CcSEcCtD
Sildenafil—Anorexia—Epirubicin—bone cancer	9.9e-05	0.000704	CcSEcCtD
Sildenafil—Dyspnoea—Methotrexate—bone cancer	9.89e-05	0.000703	CcSEcCtD
Sildenafil—Somnolence—Methotrexate—bone cancer	9.86e-05	0.000701	CcSEcCtD
Sildenafil—Dry mouth—Doxorubicin—bone cancer	9.8e-05	0.000697	CcSEcCtD
Sildenafil—Dyspepsia—Methotrexate—bone cancer	9.77e-05	0.000694	CcSEcCtD
Sildenafil—Hypotension—Epirubicin—bone cancer	9.7e-05	0.00069	CcSEcCtD
Sildenafil—ABCC4—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.69e-05	0.00194	CbGpPWpGaD
Sildenafil—Decreased appetite—Methotrexate—bone cancer	9.65e-05	0.000686	CcSEcCtD
Sildenafil—Oedema—Doxorubicin—bone cancer	9.61e-05	0.000683	CcSEcCtD
Sildenafil—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	9.6e-05	0.00192	CbGpPWpGaD
Sildenafil—Gastrointestinal disorder—Methotrexate—bone cancer	9.58e-05	0.000681	CcSEcCtD
Sildenafil—PDE6G—Signaling Pathways—GRM1—bone cancer	9.58e-05	0.00191	CbGpPWpGaD
Sildenafil—Fatigue—Methotrexate—bone cancer	9.57e-05	0.00068	CcSEcCtD
Sildenafil—Infection—Doxorubicin—bone cancer	9.54e-05	0.000679	CcSEcCtD
Sildenafil—ADORA2A—GPCR ligand binding—SMO—bone cancer	9.5e-05	0.0019	CbGpPWpGaD
Sildenafil—Pain—Methotrexate—bone cancer	9.49e-05	0.000675	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Epirubicin—bone cancer	9.46e-05	0.000673	CcSEcCtD
Sildenafil—Shock—Doxorubicin—bone cancer	9.45e-05	0.000672	CcSEcCtD
Sildenafil—PDE6G—Disease—DHFR—bone cancer	9.43e-05	0.00188	CbGpPWpGaD
Sildenafil—Nervous system disorder—Doxorubicin—bone cancer	9.42e-05	0.00067	CcSEcCtD
Sildenafil—Insomnia—Epirubicin—bone cancer	9.39e-05	0.000668	CcSEcCtD
Sildenafil—Tachycardia—Doxorubicin—bone cancer	9.38e-05	0.000667	CcSEcCtD
Sildenafil—Skin disorder—Doxorubicin—bone cancer	9.33e-05	0.000663	CcSEcCtD
Sildenafil—Paraesthesia—Epirubicin—bone cancer	9.32e-05	0.000663	CcSEcCtD
Sildenafil—Hyperhidrosis—Doxorubicin—bone cancer	9.29e-05	0.00066	CcSEcCtD
Sildenafil—Dyspnoea—Epirubicin—bone cancer	9.26e-05	0.000658	CcSEcCtD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	9.25e-05	0.00185	CbGpPWpGaD
Sildenafil—Somnolence—Epirubicin—bone cancer	9.23e-05	0.000656	CcSEcCtD
Sildenafil—Anorexia—Doxorubicin—bone cancer	9.16e-05	0.000651	CcSEcCtD
Sildenafil—Feeling abnormal—Methotrexate—bone cancer	9.14e-05	0.00065	CcSEcCtD
Sildenafil—ADORA2A—Circadian rythm related genes—CDK4—bone cancer	9.14e-05	0.00183	CbGpPWpGaD
Sildenafil—Dyspepsia—Epirubicin—bone cancer	9.14e-05	0.00065	CcSEcCtD
Sildenafil—CYP3A7—Biological oxidations—GSTP1—bone cancer	9.1e-05	0.00182	CbGpPWpGaD
Sildenafil—Gastrointestinal pain—Methotrexate—bone cancer	9.07e-05	0.000645	CcSEcCtD
Sildenafil—Decreased appetite—Epirubicin—bone cancer	9.03e-05	0.000642	CcSEcCtD
Sildenafil—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	8.98e-05	0.00179	CbGpPWpGaD
Sildenafil—Hypotension—Doxorubicin—bone cancer	8.98e-05	0.000638	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Epirubicin—bone cancer	8.96e-05	0.000637	CcSEcCtD
Sildenafil—Fatigue—Epirubicin—bone cancer	8.95e-05	0.000636	CcSEcCtD
Sildenafil—Pain—Epirubicin—bone cancer	8.88e-05	0.000631	CcSEcCtD
Sildenafil—Constipation—Epirubicin—bone cancer	8.88e-05	0.000631	CcSEcCtD
Sildenafil—Urticaria—Methotrexate—bone cancer	8.81e-05	0.000627	CcSEcCtD
Sildenafil—ADORA2A—GPCR downstream signaling—RGS1—bone cancer	8.79e-05	0.00176	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—GRM4—bone cancer	8.79e-05	0.00176	CbGpPWpGaD
Sildenafil—Abdominal pain—Methotrexate—bone cancer	8.77e-05	0.000624	CcSEcCtD
Sildenafil—Body temperature increased—Methotrexate—bone cancer	8.77e-05	0.000624	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Doxorubicin—bone cancer	8.75e-05	0.000622	CcSEcCtD
Sildenafil—Insomnia—Doxorubicin—bone cancer	8.69e-05	0.000618	CcSEcCtD
Sildenafil—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	8.65e-05	0.00173	CbGpPWpGaD
Sildenafil—Paraesthesia—Doxorubicin—bone cancer	8.63e-05	0.000613	CcSEcCtD
Sildenafil—Dyspnoea—Doxorubicin—bone cancer	8.57e-05	0.000609	CcSEcCtD
Sildenafil—Feeling abnormal—Epirubicin—bone cancer	8.56e-05	0.000608	CcSEcCtD
Sildenafil—Somnolence—Doxorubicin—bone cancer	8.54e-05	0.000607	CcSEcCtD
Sildenafil—Gastrointestinal pain—Epirubicin—bone cancer	8.49e-05	0.000604	CcSEcCtD
Sildenafil—Dyspepsia—Doxorubicin—bone cancer	8.46e-05	0.000601	CcSEcCtD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	8.44e-05	0.00169	CbGpPWpGaD
Sildenafil—Decreased appetite—Doxorubicin—bone cancer	8.35e-05	0.000594	CcSEcCtD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	8.34e-05	0.00167	CbGpPWpGaD
Sildenafil—Gastrointestinal disorder—Doxorubicin—bone cancer	8.29e-05	0.00059	CcSEcCtD
Sildenafil—Fatigue—Doxorubicin—bone cancer	8.28e-05	0.000589	CcSEcCtD
Sildenafil—Urticaria—Epirubicin—bone cancer	8.25e-05	0.000586	CcSEcCtD
Sildenafil—Constipation—Doxorubicin—bone cancer	8.22e-05	0.000584	CcSEcCtD
Sildenafil—Pain—Doxorubicin—bone cancer	8.22e-05	0.000584	CcSEcCtD
Sildenafil—Abdominal pain—Epirubicin—bone cancer	8.21e-05	0.000584	CcSEcCtD
Sildenafil—Body temperature increased—Epirubicin—bone cancer	8.21e-05	0.000584	CcSEcCtD
Sildenafil—Hypersensitivity—Methotrexate—bone cancer	8.17e-05	0.000581	CcSEcCtD
Sildenafil—ADORA2A—Signaling by GPCR—RGS1—bone cancer	7.98e-05	0.00159	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—GRM4—bone cancer	7.98e-05	0.00159	CbGpPWpGaD
Sildenafil—Asthenia—Methotrexate—bone cancer	7.96e-05	0.000566	CcSEcCtD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	7.93e-05	0.00158	CbGpPWpGaD
Sildenafil—Feeling abnormal—Doxorubicin—bone cancer	7.92e-05	0.000563	CcSEcCtD
Sildenafil—Gastrointestinal pain—Doxorubicin—bone cancer	7.86e-05	0.000559	CcSEcCtD
Sildenafil—Pruritus—Methotrexate—bone cancer	7.85e-05	0.000558	CcSEcCtD
Sildenafil—CYP2E1—Biological oxidations—CYP3A4—bone cancer	7.71e-05	0.00154	CbGpPWpGaD
Sildenafil—CYP3A5—Biological oxidations—CYP3A4—bone cancer	7.69e-05	0.00154	CbGpPWpGaD
Sildenafil—Hypersensitivity—Epirubicin—bone cancer	7.65e-05	0.000544	CcSEcCtD
Sildenafil—Urticaria—Doxorubicin—bone cancer	7.63e-05	0.000543	CcSEcCtD
Sildenafil—ADORA2A—GPCR downstream signaling—GRM1—bone cancer	7.62e-05	0.00152	CbGpPWpGaD
Sildenafil—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	7.6e-05	0.00152	CbGpPWpGaD
Sildenafil—Body temperature increased—Doxorubicin—bone cancer	7.59e-05	0.00054	CcSEcCtD
Sildenafil—Abdominal pain—Doxorubicin—bone cancer	7.59e-05	0.00054	CcSEcCtD
Sildenafil—Diarrhoea—Methotrexate—bone cancer	7.59e-05	0.00054	CcSEcCtD
Sildenafil—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	7.59e-05	0.00152	CbGpPWpGaD
Sildenafil—Asthenia—Epirubicin—bone cancer	7.45e-05	0.00053	CcSEcCtD
Sildenafil—ABCC4—Hemostasis—SPARC—bone cancer	7.45e-05	0.00149	CbGpPWpGaD
Sildenafil—Pruritus—Epirubicin—bone cancer	7.35e-05	0.000522	CcSEcCtD
Sildenafil—Dizziness—Methotrexate—bone cancer	7.34e-05	0.000522	CcSEcCtD
Sildenafil—CYP1A1—Biological oxidations—CYP3A4—bone cancer	7.27e-05	0.00145	CbGpPWpGaD
Sildenafil—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	7.17e-05	0.00143	CbGpPWpGaD
Sildenafil—Diarrhoea—Epirubicin—bone cancer	7.1e-05	0.000505	CcSEcCtD
Sildenafil—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	7.08e-05	0.00141	CbGpPWpGaD
Sildenafil—Hypersensitivity—Doxorubicin—bone cancer	7.08e-05	0.000503	CcSEcCtD
Sildenafil—Vomiting—Methotrexate—bone cancer	7.05e-05	0.000502	CcSEcCtD
Sildenafil—Rash—Methotrexate—bone cancer	7e-05	0.000497	CcSEcCtD
Sildenafil—Dermatitis—Methotrexate—bone cancer	6.99e-05	0.000497	CcSEcCtD
Sildenafil—Headache—Methotrexate—bone cancer	6.95e-05	0.000494	CcSEcCtD
Sildenafil—ADORA2A—Signaling by GPCR—GRM1—bone cancer	6.92e-05	0.00138	CbGpPWpGaD
Sildenafil—Asthenia—Doxorubicin—bone cancer	6.89e-05	0.00049	CcSEcCtD
Sildenafil—Dizziness—Epirubicin—bone cancer	6.87e-05	0.000488	CcSEcCtD
Sildenafil—PDE6G—Disease—TGFBR2—bone cancer	6.83e-05	0.00136	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—GNA11—bone cancer	6.81e-05	0.00136	CbGpPWpGaD
Sildenafil—Pruritus—Doxorubicin—bone cancer	6.8e-05	0.000483	CcSEcCtD
Sildenafil—PDE6G—Signaling Pathways—SMO—bone cancer	6.75e-05	0.00135	CbGpPWpGaD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	6.64e-05	0.00133	CbGpPWpGaD
Sildenafil—Vomiting—Epirubicin—bone cancer	6.6e-05	0.000469	CcSEcCtD
Sildenafil—CYP2E1—Biological oxidations—GSTP1—bone cancer	6.59e-05	0.00132	CbGpPWpGaD
Sildenafil—Nausea—Methotrexate—bone cancer	6.59e-05	0.000469	CcSEcCtD
Sildenafil—CYP3A5—Biological oxidations—GSTP1—bone cancer	6.58e-05	0.00131	CbGpPWpGaD
Sildenafil—Diarrhoea—Doxorubicin—bone cancer	6.57e-05	0.000467	CcSEcCtD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	6.56e-05	0.00131	CbGpPWpGaD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	6.56e-05	0.00131	CbGpPWpGaD
Sildenafil—Rash—Epirubicin—bone cancer	6.55e-05	0.000465	CcSEcCtD
Sildenafil—Dermatitis—Epirubicin—bone cancer	6.54e-05	0.000465	CcSEcCtD
Sildenafil—Headache—Epirubicin—bone cancer	6.5e-05	0.000462	CcSEcCtD
Sildenafil—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	6.5e-05	0.0013	CbGpPWpGaD
Sildenafil—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	6.49e-05	0.0013	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by NGF—KIT—bone cancer	6.49e-05	0.0013	CbGpPWpGaD
Sildenafil—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	6.46e-05	0.00129	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—NDUFA12—bone cancer	6.38e-05	0.00127	CbGpPWpGaD
Sildenafil—Dizziness—Doxorubicin—bone cancer	6.35e-05	0.000452	CcSEcCtD
Sildenafil—CYP1A1—Biological oxidations—GSTP1—bone cancer	6.22e-05	0.00124	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—IL3—bone cancer	6.18e-05	0.00123	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—GNA11—bone cancer	6.17e-05	0.00123	CbGpPWpGaD
Sildenafil—Nausea—Epirubicin—bone cancer	6.17e-05	0.000439	CcSEcCtD
Sildenafil—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	6.13e-05	0.00122	CbGpPWpGaD
Sildenafil—Vomiting—Doxorubicin—bone cancer	6.11e-05	0.000434	CcSEcCtD
Sildenafil—ADORA2A—Signaling by NGF—BRAF—bone cancer	6.1e-05	0.00122	CbGpPWpGaD
Sildenafil—Rash—Doxorubicin—bone cancer	6.06e-05	0.000431	CcSEcCtD
Sildenafil—Dermatitis—Doxorubicin—bone cancer	6.05e-05	0.00043	CcSEcCtD
Sildenafil—Headache—Doxorubicin—bone cancer	6.02e-05	0.000428	CcSEcCtD
Sildenafil—CYP2C19—Biological oxidations—CYP3A4—bone cancer	5.95e-05	0.00119	CbGpPWpGaD
Sildenafil—ADORA2A—Circadian rythm related genes—JUN—bone cancer	5.89e-05	0.00118	CbGpPWpGaD
Sildenafil—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	5.87e-05	0.00117	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—ATF1—bone cancer	5.74e-05	0.00115	CbGpPWpGaD
Sildenafil—Nausea—Doxorubicin—bone cancer	5.71e-05	0.000406	CcSEcCtD
Sildenafil—PDE6G—Signaling Pathways—IL3—bone cancer	5.59e-05	0.00112	CbGpPWpGaD
Sildenafil—ABCC5—Disease—ENO2—bone cancer	5.49e-05	0.0011	CbGpPWpGaD
Sildenafil—CYP2D6—Biological oxidations—CYP3A4—bone cancer	5.47e-05	0.00109	CbGpPWpGaD
Sildenafil—CYP2C9—Biological oxidations—CYP3A4—bone cancer	5.42e-05	0.00108	CbGpPWpGaD
Sildenafil—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	5.4e-05	0.00108	CbGpPWpGaD
Sildenafil—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	5.35e-05	0.00107	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—NT5C3A—bone cancer	5.29e-05	0.00106	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by NGF—MDM2—bone cancer	5.11e-05	0.00102	CbGpPWpGaD
Sildenafil—ABCC5—Disease—DHFR—bone cancer	5.09e-05	0.00102	CbGpPWpGaD
Sildenafil—CYP2C19—Biological oxidations—GSTP1—bone cancer	5.09e-05	0.00102	CbGpPWpGaD
Sildenafil—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	5.02e-05	0.001	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—GNA11—bone cancer	4.91e-05	0.000981	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—SMO—bone cancer	4.88e-05	0.000974	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—TGFBR2—bone cancer	4.79e-05	0.000956	CbGpPWpGaD
Sildenafil—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.72e-05	0.000943	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—GRM4—bone cancer	4.71e-05	0.000942	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—RGS1—bone cancer	4.71e-05	0.000942	CbGpPWpGaD
Sildenafil—CYP2D6—Biological oxidations—GSTP1—bone cancer	4.68e-05	0.000935	CbGpPWpGaD
Sildenafil—PDE6G—Disease—KIT—bone cancer	4.66e-05	0.000931	CbGpPWpGaD
Sildenafil—CYP2C9—Biological oxidations—GSTP1—bone cancer	4.64e-05	0.000927	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—NDUFA12—bone cancer	4.62e-05	0.000923	CbGpPWpGaD
Sildenafil—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	4.62e-05	0.000922	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—NDUFA12—bone cancer	4.61e-05	0.000921	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—ENO2—bone cancer	4.6e-05	0.000918	CbGpPWpGaD
Sildenafil—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	4.58e-05	0.000914	CbGpPWpGaD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	4.54e-05	0.000907	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—IGF1R—bone cancer	4.5e-05	0.000899	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—GNA11—bone cancer	4.46e-05	0.000891	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—IL3—bone cancer	4.45e-05	0.000889	CbGpPWpGaD
Sildenafil—PDE6G—Disease—BRAF—bone cancer	4.38e-05	0.000875	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—NDUFA12—bone cancer	4.36e-05	0.00087	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—DHFR—bone cancer	4.26e-05	0.000852	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—TP53—bone cancer	4.24e-05	0.000847	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—GRM1—bone cancer	4.09e-05	0.000817	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—PLAU—bone cancer	4.05e-05	0.000809	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—IL3—bone cancer	4.04e-05	0.000808	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—GNA11—bone cancer	3.99e-05	0.000796	CbGpPWpGaD
Sildenafil—ADORA2A—Circadian rythm related genes—TP53—bone cancer	3.89e-05	0.000777	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—NT5C3A—bone cancer	3.83e-05	0.000765	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—NT5C3A—bone cancer	3.82e-05	0.000763	CbGpPWpGaD
Sildenafil—ABCC5—Disease—TGFBR2—bone cancer	3.69e-05	0.000737	CbGpPWpGaD
Sildenafil—PDE6G—Disease—MDM2—bone cancer	3.67e-05	0.000734	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—CYP3A4—bone cancer	3.61e-05	0.000722	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—NT5C3A—bone cancer	3.61e-05	0.000721	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—NDUFA12—bone cancer	3.57e-05	0.000712	CbGpPWpGaD
Sildenafil—PDE6G—Disease—PTGS2—bone cancer	3.54e-05	0.000707	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by NGF—EGFR—bone cancer	3.49e-05	0.000698	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—NDUFA12—bone cancer	3.28e-05	0.000655	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—KIT—bone cancer	3.27e-05	0.000652	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NDUFA12—bone cancer	3.25e-05	0.000649	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—GSTP1—bone cancer	3.09e-05	0.000617	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—BRAF—bone cancer	3.07e-05	0.000613	CbGpPWpGaD
Sildenafil—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.06e-05	0.000611	CbGpPWpGaD
Sildenafil—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.02e-05	0.000603	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—NT5C3A—bone cancer	2.95e-05	0.00059	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—SMO—bone cancer	2.88e-05	0.000575	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—NT5C3A—bone cancer	2.72e-05	0.000543	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NT5C3A—bone cancer	2.69e-05	0.000538	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—GNA11—bone cancer	2.63e-05	0.000526	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—MDM2—bone cancer	2.57e-05	0.000514	CbGpPWpGaD
Sildenafil—ABCC5—Disease—KIT—bone cancer	2.52e-05	0.000503	CbGpPWpGaD
Sildenafil—PDE6G—Disease—EGFR—bone cancer	2.51e-05	0.000501	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—ATF1—bone cancer	2.45e-05	0.000489	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—IL3—bone cancer	2.39e-05	0.000477	CbGpPWpGaD
Sildenafil—ABCC5—Disease—BRAF—bone cancer	2.37e-05	0.000473	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—ENO2—bone cancer	2.32e-05	0.000463	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—JUN—bone cancer	2.24e-05	0.000446	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—MMP9—bone cancer	2.17e-05	0.000434	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—DHFR—bone cancer	2.15e-05	0.000429	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NDUFA12—bone cancer	2.14e-05	0.000428	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—TGFBR2—bone cancer	2.04e-05	0.000408	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—GNA11—bone cancer	2.01e-05	0.000401	CbGpPWpGaD
Sildenafil—ABCC5—Disease—MDM2—bone cancer	1.98e-05	0.000396	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—IGF1R—bone cancer	1.92e-05	0.000384	CbGpPWpGaD
Sildenafil—ABCC5—Disease—PTGS2—bone cancer	1.91e-05	0.000382	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—CYP3A4—bone cancer	1.82e-05	0.000364	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NT5C3A—bone cancer	1.78e-05	0.000355	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—EGFR—bone cancer	1.76e-05	0.000351	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—ENO2—bone cancer	1.68e-05	0.000335	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—ENO2—bone cancer	1.67e-05	0.000334	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—TP53—bone cancer	1.63e-05	0.000325	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—PTGS2—bone cancer	1.6e-05	0.00032	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—ENO2—bone cancer	1.58e-05	0.000316	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—GSTP1—bone cancer	1.56e-05	0.000311	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—DHFR—bone cancer	1.56e-05	0.000311	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—DHFR—bone cancer	1.55e-05	0.00031	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—TP53—bone cancer	1.48e-05	0.000295	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—DHFR—bone cancer	1.47e-05	0.000293	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—GNA11—bone cancer	1.45e-05	0.000291	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—GNA11—bone cancer	1.45e-05	0.00029	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—KIT—bone cancer	1.39e-05	0.000278	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—GNA11—bone cancer	1.37e-05	0.000274	CbGpPWpGaD
Sildenafil—ABCC5—Disease—EGFR—bone cancer	1.36e-05	0.000271	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—CYP3A4—bone cancer	1.32e-05	0.000263	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—CYP3A4—bone cancer	1.32e-05	0.000263	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—BRAF—bone cancer	1.31e-05	0.000262	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—ENO2—bone cancer	1.29e-05	0.000259	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—EGFR—bone cancer	1.27e-05	0.000254	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—CYP3A4—bone cancer	1.24e-05	0.000248	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.24e-05	0.000247	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—DHFR—bone cancer	1.2e-05	0.00024	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—ENO2—bone cancer	1.19e-05	0.000238	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—ENO2—bone cancer	1.18e-05	0.000236	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—GSTP1—bone cancer	1.13e-05	0.000225	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—GSTP1—bone cancer	1.13e-05	0.000225	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—GNA11—bone cancer	1.12e-05	0.000224	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—DHFR—bone cancer	1.1e-05	0.000221	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—MDM2—bone cancer	1.1e-05	0.000219	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—DHFR—bone cancer	1.09e-05	0.000219	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—GSTP1—bone cancer	1.06e-05	0.000212	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—GNA11—bone cancer	1.03e-05	0.000206	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—GNA11—bone cancer	1.02e-05	0.000204	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—CYP3A4—bone cancer	1.02e-05	0.000203	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.01e-05	0.000202	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—JUN—bone cancer	9.54e-06	0.000191	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—CYP3A4—bone cancer	9.36e-06	0.000187	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—MMP9—bone cancer	9.28e-06	0.000185	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—CYP3A4—bone cancer	9.28e-06	0.000185	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.23e-06	0.000184	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—GSTP1—bone cancer	8.7e-06	0.000174	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—PTGS2—bone cancer	8.07e-06	0.000161	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—GSTP1—bone cancer	8e-06	0.00016	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—GSTP1—bone cancer	7.93e-06	0.000158	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ENO2—bone cancer	7.78e-06	0.000155	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—EGFR—bone cancer	7.5e-06	0.00015	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—DHFR—bone cancer	7.22e-06	0.000144	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GNA11—bone cancer	6.75e-06	0.000135	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—TP53—bone cancer	6.3e-06	0.000126	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—PTGS2—bone cancer	5.84e-06	0.000117	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PTGS2—bone cancer	5.83e-06	0.000116	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—PTGS2—bone cancer	5.51e-06	0.00011	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GSTP1—bone cancer	5.23e-06	0.000105	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PTGS2—bone cancer	4.51e-06	9e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PTGS2—bone cancer	4.15e-06	8.28e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PTGS2—bone cancer	4.11e-06	8.21e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PTGS2—bone cancer	2.71e-06	5.41e-05	CbGpPWpGaD
